Search
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalLinvoseltamab (INN), marketed as Lynozyficâ„¢, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells. B...
Goserelin
go.drugbank.com/drugs/DB00014ApprovedInvestigationalGoserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the...
Thalidomide
go.drugbank.com/drugs/DB01041ApprovedInvestigationalWithdrawnA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thal...
International brands: Pro-ban MBromothalonil
go.drugbank.com/drugs/DB14199ApprovedIt is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy [A34322].
Digoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigationalDigoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the...
Dexpanthenol
go.drugbank.com/drugs/DB09357ApprovedInvestigationalDexpanthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium.
Mixtures: Multivit Et Fer Ampoules Et Comprimes, Dynam Ampoule Et TabletCategories: Vitamin B ComplexVerteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Oxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]